AtaiBeckley Inc. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
3.730
-0.610 (-14.06%)
At close: Feb 26, 2026, 4:00 PM EST
3.730
0.00 (0.00%)
After-hours: Feb 26, 2026, 7:59 PM EST
AtaiBeckley Revenue
AtaiBeckley had revenue of $749.00K in the quarter ending September 30, 2025, with 1,772.50% growth. This brings the company's revenue in the last twelve months to $3.02M, up 811.78% year-over-year. In the year 2024, AtaiBeckley had annual revenue of $308.00K, down -1.91%.
Revenue (ttm)
$3.02M
Revenue Growth
+811.78%
P/S Ratio
448.87
Revenue / Employee
$55,889
Employees
54
Market Cap
1.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 308.00K | -6.00K | -1.91% |
| Dec 31, 2023 | 314.00K | 81.00K | 34.76% |
| Dec 31, 2022 | 233.00K | -20.14M | -98.86% |
| Dec 31, 2021 | 20.38M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 1.06B |
| Harmony Biosciences Holdings | 868.45M |
| Ardelyx | 407.32M |
| Immunocore Holdings | 400.02M |
| Iovance Biotherapeutics | 263.50M |
| Nurix Therapeutics | 83.98M |
| Intellia Therapeutics | 57.53M |
| uniQure | 15.75M |
ATAI News
- 10 hours ago - AtaiBeckley Touts Social Anxiety Breakthrough With Phase 2 Trial Data - Benzinga
- 13 hours ago - AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder - GlobeNewsWire
- 6 days ago - AtaiBeckley To Host Virtual Investor Day on March 6, 2026 - GlobeNewsWire
- 5 weeks ago - AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation - GlobeNewsWire
- 7 weeks ago - AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI) - GlobeNewsWire
- 3 months ago - Enhanced Fortifies Executive Leadership Team & Board of Directors - PRNewsWire
- 3 months ago - Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression Transcript - Seeking Alpha